Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Latest Heart Valve Replacement Technology Improves Outcomes for High-Risk Patients
Clinical Breakthroughs

Latest Heart Valve Replacement Technology Improves Outcomes for High-Risk Patients

By Nora DunneJul 26, 2016
Share
Facebook Twitter Email
The study assessed a third generation replacement valve to treat high-risk and inoperable patients with severe aortic stenosis.
The study assessed a third generation replacement valve to treat high-risk and inoperable patients with severe aortic stenosis.

High-risk and inoperable patients with severe aortic stenosis had very low rates of complications and mortality after undergoing a minimally invasive procedure to repair their condition using a new generation replacement valve, according to research published in the journal Circulation.

Open-heart surgery was once the most effective way to treat aortic stenosis, a narrowing of the aortic valve that limits blood flow to the heart. But recently, transcatheter aortic valve replacement (TAVR), which involves implanting a collapsible valve into the heart through a catheter, has become a promising and less invasive alternative to surgery. The new study assessed the latest version of a valve called SAPIEN 3 that is used in the procedure.

In the study, one-year survival for patients that received SAPIEN 3 was 85 percent. Older TAVR systems have had survival rates of 69 to 76 percent for the same types of patients in previous research.

“With this new data, we believe that TAVR using the current generation device is the preferred choice for older, sicker patients, over surgical aortic valve replacement,” said S. Chris Malaisrie, MD, associate professor of Surgery in the Division of Cardiac Surgery, who led the study’s Northwestern site. “With earlier generation devices, I think it was a toss up, but now TAVR is definitely the preferred choice. These findings will likely lead to some guideline changes.”

The research included 583 patients who had a high risk of surgical mortality or were considered inoperable because of comorbidities, all treated with SAPIEN 3 throughout 29 sites in the United States. In previously published research, Malaisrie and colleagues assessed the same replacement valve in intermediate-risk patients, with similarly positive results. Next, they plan to test the technology in low-risk patients. Malaisrie just enrolled his first patient for that study.

“We’re always looking for the most effective treatments for patients that carry the least amount of risks,” Malaisrie said. “We know that as technology improves, the safety and efficacy of all these devices that we use should also improve.”

This study was funded by Edwards Lifesciences, the manufacturer of the SAPIEN 3 transcatheter valve. Malaisrie did not receive compensation from the company for his work in the trial.

Cardiology Patient Care Research
Share. Facebook Twitter Email

Related Posts

Global Health Day Highlights Pandemic, HIV Research

Dec 8, 2023

AI May Spare Breast Cancer Patients Unnecessary Treatments

Dec 7, 2023

Drug Extends Survival in Prostate Cancer with Genetic Mutations  

Dec 6, 2023

Comments are closed.

Latest News

Global Health Day Highlights Pandemic, HIV Research

Dec 8, 2023

AI May Spare Breast Cancer Patients Unnecessary Treatments

Dec 7, 2023

Drug Extends Survival in Prostate Cancer with Genetic Mutations  

Dec 6, 2023

Pioneering Biochemist Craig Crews Named Winner of 2024 Kimberly Prize

Dec 5, 2023

Family Language Tied to Hospitalization Rates in Feverish Babies

Dec 5, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
2023-Sim-Open-House_161
2023-Sim-Open-House_127
2023-Sim-Open-House_108
2023-Sim-Open-House_106
2023-Sim-Open-House_118
2023-Sim-Open-House_068
2023-Sim-Open-House_069
2023-Sim-Open-House_027
2023-Sim-Open-House_155
2023-Sim-Open-House_161
2023-Sim-Open-House_127
2023-Sim-Open-House_108

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.